Protagonist Therapeutics $300 Million Share Repurchase
Analysis based on 8 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The announcement signals confidence in Protagonist's financial strength and future cash flows, likely supporting its stock price. The repurchase program, funded by strong cash reserves and expected milestone payments, may enhance shareholder value and positively influence investor sentiment.
On September 8, 2026, AnBogen Therapeutics announced that its Board of Directors authorized a share repurchase program of up to $300 million of its outstanding common stock. The company plans to fund the repurchases using its cash, cash equivalents, and marketable securities, as well as royalties and payments from its collaboration agreements with Takeda Pharmaceutical Company (related to MIMRYLO/rusfertide) and Johnson & Johnson (related to ICOTYDE/icotrokinra). As of June 30, 2026, Protagonist held $849.5 million in cash and marketable securities, excluding a $200 million opt-out payment and a $75 million milestone payment earned in August 2026 under the Takeda agreement, which are expected to be received in Q4 2026. The repurchase program is flexible and may be modified, suspended, or discontinued at any time. Protagonist is a biopharmaceutical company with two FDA-approved medicines, ICOTYDE and MIMRYLO, developed in partnership with Johnson & Johnson and Takeda.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard